A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies

Part of paid clinical trials in Eden Prairie, Minnesota.

Sponsor
Biogen
Study ID
NCT05688436
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 49 Years
Healthy Volunteers
Not accepted

Interventions

  • Diroximel Fumarate — DRUG
    Administered as specified in the treatment arm.
  • Alemtuzumab — BIOLOGICAL
    Administered as specified in the treatment arm.
  • Fingolimod — DRUG
    Administered as specified in the treatment arm.
  • Glatiramer acetate — DRUG
    Administered as specified in the treatment arm.
  • Interferon beta — BIOLOGICAL
    Administered as specified in the treatment arm.
  • Natalizumab — BIOLOGICAL
    Administered as specified in the treatment arm.
  • Ocrelizumab — BIOLOGICAL
    Administered as specified in the treatment arm.
  • Ofatumumab — BIOLOGICAL
    Administered as specified in the treatment arm.
  • Ozanimod — DRUG
    Administered as specified in the treatment arm.
  • Peginterferon beta-1a — BIOLOGICAL
    Administered as specified in the treatment arm.
  • Ponesimod — DRUG
    Administered as specified in the treatment arm.
  • Siponimod — DRUG
    Administered as specified in the treatment arm.

Study Details

In this study, researchers will learn more about the effects of diroximel fumarate (DRF), also known as VUMERITY®, when taken during pregnancy in people with multiple sclerosis, also known as MS. In MS, the immune system attacks the nerves in the brain and spinal cord. The affected areas are called lesions. The damage makes it difficult for the brain and spinal cord to function and send messages throughout the body. MS can be a progressive disease, which means it may get worse over time. In relapsing forms of MS (RMS), new symptoms may happen, and existing symptoms may get better or worse over time. DRF is an approved drug that is used to treat people with RMS. This is known as an "observational" study, which collects health information about study participants without changing their medical care. The main goal of this study is to collect birth and health information from 3 groups of participants and their babies. These groups are: * Those who took DRF during their pregnancy * Those who took disease-modifying therapies (DMTs) for RMS during their pregnancy, but not DRF. DMTs are drugs that slow how the disease develops over time, not just relieve symptoms. * Those who did not take any drugs for RMS during their pregnancy The main question researchers want to learn about in this study is: • How many participants' babies were born with major congenital malformations (MCMs)? MCMs are problems with how a baby's body forms before birth. In this study, researchers will measure how often the following outcomes happen and compare them between groups: * Loss of pregnancy before 20 weeks * Loss of pregnancy at or after 20 weeks (stillbirth) * Babies born early (before 37 weeks) * Babies who are smaller than expected for the stage of pregnancy * Live births This study will be done as follows: * The study includes data in adult women with multiple sclerosis on pregnancies happening between October 29th, 2019 and July 31st, 2030. Information will start being collected when the participant decides to join the study. * Medical records and clinical notes will be reviewed at the end of the study. * The study will include information from pregnancy through delivery, and for babies up to 1 year after birth. * The study is planned to end by 30th April 2031.

Key Dates

Start date
Sep 24, 2021
Status verified
Jun 2026
Primary completion
Jan 17, 2031
Completion
Jan 17, 2031

Study Design

Enrollment
1,178 participants (estimated)

Arms

  • Arm: Diroximel Fumarate (DRF)
    Pregnant women with MS who were exposed to DRF.
  • Arm: Non-DRF
    Pregnant women with MS who were exposed to disease-modifying therapies (DMTs) other than DRF.
  • Arm: Non-DMT
    Pregnant women with MS who were not exposed to DMTs.

Primary Outcome Measure

Number of Major Congenital Malformations (MCMs) [ Time Frame: Up to 52 weeks postdelivery ]

Locations (1)

FacilityCityStateZIPSite coordinators
OptumInsightEden PrairieMinnesota55344-2503-

Find similar trials in Eden Prairie, MN

By condition
Multiple sclerosis
By specialty
NeurologyBrain disordersAutoimmune disease
By research site
OptumInsight· Eden Prairie, MN

Related Studies